Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3802876 in Compensated Cirrhosis Due to MASH
NCT07325526Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of bi 3802876 in metabolic dysfunction-associated steatohepatitis (MASH) and Liver cirrhosis (LC) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any Adverse Events up to 134 days. Started Feb 2026; status: recruiting.
02
Drugs
bi 3802876
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07325526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325526.